BioCorRX Inc. Discusses FDA Approval Process for Implantable Naltrexone Pellet, BICX104, with The Stock Day Podcast

By: Newsfile

Phoenix, Arizona--(Newsfile Corp. - April 19, 2022) - The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Director, CEO, and CFO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's background and current projects. "We have been in business now for over ten years," said Felix. "We started out as strictly a healthcare company back in 2009 and went into biotechnology and pharmaceuticals in 2016," she continued. "Our solutions are geared towards addictive disorders, as well as R&D."

"What is the latest update on the FDA approval for BICX104?" asked Jolly. "It is an implantable naltrexone pellet for treatment of alcohol and opioid use disorders," said Felix. "Right now we're going through the process of taking that through FDA approval, and we have received a grant from NIDA," she shared. "Right now, we are getting ready to start clinical trials."

"What does your treatment program look like?" asked Jolly. "We do have our Beat Addiction Recovery program," said Felix. "It consists of medication assisted treatment, which can come in many forms, and it is combined with peer support, as well as cognitive behavioral therapy (CBT)."

"How big is the market for BICX104?" asked Jolly. "There are millions of individuals suffering from addiction," shared Felix. "The goal here is to offer as many options as are available to the medical community," she said. "We know the medication, naltrexone, very well. We could not be more excited to continue to offer our Beat Addiction program and then also potentially introduce a new FDA approved product in the next couple of years."

"What are the latest developments for your weight loss program?" asked Jolly. "That is our newest program," said Felix. "It is a super comprehensive program," she added. "It is a medically assisted weight loss program. The medication, naltrexone, may also help with food cravings based on some previous studies," she explained. "The very unique component of our weight loss program is the app that accompanies the program," said Felix. "This is something that is very different and very unique."

To close the interview, Felix encouraged listeners and shareholders to keep up-to-date on the Company's upcoming and current projects, and to reach out to with any questions.

To hear Lourdes Felix's entire interview, follow the link to the podcast here:

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304

Media Contact:
CMW Media
(858) 264-6600

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.